Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | JMJD1C | Q15652 | 1/20 | 0.36 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14965691 | 0.87 | ADORA3 (0.36) | SYKADORA3TSHRMC4RADRA1A | |
| SCHEMBL31506349 | 0.83 | KDM4E (0.49) | SYKTSHRKDM4EKDM5AJMJD1C | |
| SCHEMBL13043849 | 0.83 | ALDH1A1 (0.42) | SYKPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2627832 | 0.83 | KDM4E (0.49) | SYKTSHRKDM4EKDM5AJMJD1C | |
| SCHEMBL3743806 | 0.81 | KDM4E (0.47) | SYKTSHRKDM4EKDM5AJMJD1C | |
| SCHEMBL13043958 | 0.81 | GABRP (0.35) | SYKPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2791548 | 0.81 | KMT2A (0.47) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL24925529 | 0.81 | P2RX7 (0.49) | SYKADORA3KDM4EKDM5AJMJD1C | |
| Lithium Ion SCHEMBL3743801 | 0.80 | SYK (0.33) | SYKPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL24925458 | 0.80 | KDM4E (0.35) | SYKPIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | claimed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | claimed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | claimed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | claimed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | claimed |
| US-20230022696-A1 | SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND HISTONE DEACTYLASES AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-01-26 | — | — | US | disclosed |
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-07-28 | — | — | US | disclosed |
| US-10570118-B2 | Isoquinolones as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| US-20190023686-A1 | ISOQUINOLONES AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| WO-2010121814-A1 | PHARMACEUTICAL COMPOSITION, COMPRISING A STEROID-DEHYDROGENASE-REDUCTASE INHIBITOR, AND A MINERALOCORTICOID RECEPTOR ANTAGONIST | ONTOCHEM GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022696-A1 | SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND HISTONE DEACTYLASES AND USES THEREOF | HDAC5, HDAC4, HDAC7 | SYK 3580/4885PIK3CA 2728/4885PIK3CD 2536/4885 |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | HSD11B1, HSD17B1, HSD3B1 | SYK 4690/4885PIK3CA 2153/4885PIK3CD 3083/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | SYK 21/4885PIK3CA 494/4885PIK3CD 460/4885 |
| US-10570118-B2 | Isoquinolones as BTK inhibitors | BTK, SYK, LYN | SYK 2/4885PIK3CA 20/4885PIK3CD 29/4885 |
| US-20190023686-A1 | ISOQUINOLONES AS BTK INHIBITORS | BTK, SYK, LYN | SYK 2/4885PIK3CA 20/4885PIK3CD 29/4885 |
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | SYK 1300/4885PIK3CA 311/4885PIK3CD 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.